Abstract 3485
Background
Fruquintinib is a potent, highly selective, novel vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor. In the phase 3 FRESCO trial1 that led to the drug’s approval in China, fruquintinib improved the median overall survival in patients with metastatic colorectal cancer (mCRC) in a third-line or later setting when compared to placebo (9.3 vs 6.6 months); hazard ratio was 0.65 (95% CI, 0.51-0.83; P < 0.001).
Methods
This is a phase 1, open-label, dose escalation/dose expansion study conducted in the United States. The primary objectives are to evaluate the safety and tolerability in patients (pts) with advanced solid tumors and to determine the recommended phase 2 dose (RP2D). A secondary objective is to evaluate anticancer activity. The dose cohorts, 3 mg and 5 mg qd, were each on a 3 weeks on, 1 week off (3/1) schedule.
Results
There were 7 pts (6 evaluable) in each dose cohort (14 total). One patient in the 3 mg cohort had a dose-limiting toxicity (DLT) of grade 4 hypertension, and no patient in the 5 mg cohort had a DLT. The RP2D was determined to be 5 mg qd (3/1). Two other serious adverse events, colon obstruction and left breast cellulitis, were reported; neither was suspected to be drug-related. All 14 pts reported AEs; the most common were vomiting (57%), nausea (50%), constipation (50%, proteinuria (50%), hypertension (50%), dysphonia (43%), anorexia (36%), and dyspepsia (36%). Of the 10 pts evaluable for best objective response, 3 had a partial response, 5 had stable disease, and 1 had disease progression. Objective response rate was 3/14 (21.4%) and disease control rate was 9/14 (64.3%). Mean duration on study drug was 5.3 months.
Conclusions
Fruquintinib is generally well-tolerated in heavily pretreated patients, with the safety profile consistent with that of other anti-angiogenic tyrosine kinase inhibitors. The RP2D in US pts is 5 mg qd (3/1), which is also the approved dose in China. Preliminary anticancer activity was evident in these pts with advanced solid tumors. The dose expansion phase of the study is ongoing. Further investigation of fruquintinib in pts with mCRC is planned. 1 JAMA 2018; 319:2486.
Clinical trial identification
NCT03251378.
Editorial acknowledgement
Hoang-Lan Nguyen, PhD, Hutchison MediPharma (US), Inc.
Legal entity responsible for the study
Hutchison MediPharma, Limited.
Funding
Hutchison MediPharma, Limited.
Disclosure
A. Wang-Gillam: Advisory / Consultancy: Tyme; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Bristol-Myer Squibb; Advisory / Consultancy: Jacobio. H. Park: Research grant / Funding (institution): Ambrx; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Array Biopharma; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Daichi Pharmaceutical; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Gilead; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Hoffman-LaRoche; Research grant / Funding (institution): Immunomedics; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Millenium; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Puma Biotechnology; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Vertex Pharmaceuticals; Research grant / Funding (institution): Xencor. F. Songhua: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. N.P. Sauter: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. M. Kania: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract